Zelluna: Scientist turns CEO
In 2018, Hassan joined Zelluna as CSO from Immunocore Ltd where he was responsible for building the biology, preclinical and biomarker organisations in oncology. He also led development and a first-in-human trial in metastatic melanoma. Hassan also created and built an infectious disease unit, including pipeline development and secured an investment of up to USD 40 million from the Gates foundation.
Previously, Hassan had a leadership role in the discovery research organization within GSK, and has worked at the Ludwig Institute for Cancer Research. He received a DPhil from the University of Oxford in T-cell Biology.
Zelluna Immunotherapy develops transformative T cell receptor based cellular immunotherapies for the treatment of solid cancers.